Table 1. Baseline characteristics and risk factors.
| Characteristic | All women (n = 298) | cTFC ≤35 n = 179 | cTFC >35 n = 119 | P (unad-justed) | P (age-adjusted) | |
| Demographics | ||||||
| Age (y) | 55±11 | 56±11 | 54±10 | 0.20 | - | |
| Postmenopausal (%)** | 210/296 (71) | 72 | 69 | 0.53 | - | |
| White race (%) | 257 (86) | 90 | 80 | 0.009 | 0.013 | |
| HS educ. or more (%) | 243/294 (83) | 82 | 83 | 0.97 | 0.94 | |
| Body size | ||||||
| Waist circumference (in) | 36.8±6.8 | 36.0±5.5 | 38.2±8.5 | 0.027 | 0.020 | |
| BMI | 30.3±7.1 | 29.8±6.6 | 31.0±7.8 | 0.17 | 0.20 | |
| Waist/hip ratio | 0.85±0.12 | 0.85±0.11 | 0.87±0.14 | 0.20 | 0.18 | |
| Self-reported risk factors | ||||||
| Hx diabetes (%) | 42/297 (14) | 11 | 19 | 0.07 | 0.053 | |
| Family hx of CAD (%) | 181/290 (62) | 59 | 67 | 0.16 | 0.18 | |
| Hx hypertension (%) | 143/296 (48) | 47 | 51 | 0.48 | 0.34 | |
| Hx dyslipidemia (%) | 116/275 (42) | 43 | 40 | 0.65 | 0.74 | |
| Ever smoker (%) | 151/297 (51) | 54 | 47 | 0.24 | 0.20 | |
| Current smoker (%) | 58/297 (20) | 20 | 19 | 0.75 | 0.50 | |
| High stress (%) | 117 (39) | 40 | 39 | 0.86 | 0.70 | |
| Hemodynamic measures | ||||||
| Systolic BP (mmHg) | 133±20 | 134±20 | 131±19 | 0.21 | 0.33 | |
| Diastolic BP (mmHg) | 76±10 | 77±11 | 76±10 | 0.37 | 0.34 | |
| Pulse pressure | 57±16 | 58±16 | 56±16 | 0.25 | 0.44 | |
| Mean arterial pressure | 95±12 | 96±12 | 94±11 | 0.22 | 0.28 | |
| Lab values | ||||||
| LDL-C (mg/dl) | 111±37 | 112±39 | 109±33 | 0.52 | 0.58 | |
| HDL (mg/dl) | 53±13 | 53±13 | 53±13 | 0.99 | 0.82 | |
| Triglycerides (mg/dl) (medians[IQR])* | 113 [72, 169] | 122 [76, 169] | 96 [70, 172] | 0.37 | 0.55* | |
| Total cholesterol | 191±43 | 192±44 | 191±41 | 0.92 | 0.94 | |
| Fasting blood glucose | 104±39 | 103±38 | 107±40 | 0.33 | 0.31 | |
| Creatinine (mg/dl) | 0.79±0.18 | 0.80±0.19 | 0.78±0.16 | 0.48 | 0.61 | |
| Hemoglobin (g/dl) | 13.0±1.4 | 13.1±1.4 | 12.9±1.3 | 0.25 | 0.21 | |
| Medication use | ||||||
| Any antihypertensive use (%) | 167/283 (59) | 60 | 57 | 0.62 | 0.74 | |
| Any lipid lowering meds (%) | 52/297 (18) | 19 | 15 | 0.41 | 0.45 | |
| Ever HRT use (%) | 160/293 (55) | 56 | 52 | 0.42 | 0.55 | |
| Current HRT use (%) | 116/294 (39) | 40 | 38 | 0.70 | 0.83 | |
| Statins (%) | 39/297 (13) | 13 | 14 | 0.86 | 0.77 | |
| ACE inhibitors (%) | 51/269 (19) | 18 | 20 | 0.66 | 0.51 | |
| Beta blockers (%) | 89/297 (30) | 29 | 31 | 0.67 | 0.65 | |
| Aspirin (%) | 138/296 (47) | 49 | 42 | 0.23 | 0.27 | |
| Diuretics (%) | 63/297 (21) | 19 | 24 | 0.25 | 0.19 | |
| Other variables | ||||||
| CAD severity score (medians[IQR])* | 5.0 [5.0, 7.5] | 5.0 [5.0, 7.5] | 5.0 [5.0, 6.2] | 0.57 | 0.72* | |
| Functional capacity (DASI) | 21.4±14.9 | 22.6±15.3 | 19.7±14.2 | 0.11 | 0.10 | |
| Unstable angina past 6 wks | 74/266 (28) | 27 | 29 | 0.72 | 0.81 |
cTFC = corrected TIMI frame count; HS educ = High School education; BMI = body mass index; Hx = history; HRT = hormone replacement therapy; CAD = coronary artery disease.
*Because of skewed distribution, medians [interquartile ranges] are given and Log transformations were used to estimate the age-adjusted p-values.
**For frequencies, where there were missing values, the statistic given is: no. with the condition/no. available (%).